Compare Abbott Laboratories (ABT) vs Altria Group Inc (MO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Altria Group Inc — how do they compare? Abbott Laboratories trades at $95.68 (market cap $166.94B), while Altria Group Inc trades at $73.38 (market cap $121.84B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Altria Group Inc pays the higher dividend (5.81%). Which is the better fit depends on your goals.
| ABT | MO | |
|---|---|---|
Market Cap | $166.94B | $121.84B |
Sector | Health | Consumer Staples |
52-Week High | $136.62 | $74.55 |
52-Week Low | $82.57 | $54.72 |
Enterprise Value | $193.69B | $142.91B |
Dividend Yield | 2.63% | 5.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
MO trades at $72.96, up 0.34% today, with a bullish technical signal from moving averages and a neutral RSI near 60. The stock shows strong profitability with a 39.52% net margin and consistent cash flow, though revenue has been flat near $20.1B. Analysts are largely positive, with 62% recommending Buy and a consensus target of $70.75. Recent news highlights its appeal as a dividend king for income investors, with a $1.06 dividend paid in July 2026.
Outlook: MO offers stable income with high margins and dividend reliability, but faces risks from debt levels and regulatory pressures. The stock is near analyst targets, suggesting limited upside, yet remains a defensive hold for yield-seeking portfolios amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →
